Voyager Therapeutics (NASDAQ:VYGR) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other research firms have also commented on VYGR. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 11th. HC Wainwright reduced their target price on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.75.

Voyager Therapeutics Trading Up 2.0%

VYGR stock opened at $3.49 on Friday. The firm has a 50 day moving average of $3.89 and a 200-day moving average of $4.10. The firm has a market capitalization of $194.04 million, a P/E ratio of -1.62 and a beta of 1.30. Voyager Therapeutics has a 12 month low of $2.64 and a 12 month high of $5.55.

Insider Activity

In related news, CEO Alfred Sandrock sold 12,192 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $3.78, for a total value of $46,085.76. Following the completion of the transaction, the chief executive officer directly owned 509,989 shares in the company, valued at approximately $1,927,758.42. The trade was a 2.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 20,286 shares of company stock worth $77,248. Insiders own 6.39% of the company’s stock.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can purchased a new position in shares of Voyager Therapeutics in the 2nd quarter worth about $36,000. Wexford Capital LP purchased a new stake in Voyager Therapeutics in the third quarter worth approximately $42,000. ProShare Advisors LLC bought a new position in Voyager Therapeutics during the fourth quarter valued at approximately $44,000. CIBC Asset Management Inc purchased a new position in shares of Voyager Therapeutics during the fourth quarter worth approximately $45,000. Finally, R Squared Ltd bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth approximately $48,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.